Dr Lucia Rosario Dimeo, PHD | |
55 Company Street, Christiansted, St. Croix, VI 00820 | |
(340) 713-9029 | |
(340) 713-0179 |
Full Name | Dr Lucia Rosario Dimeo |
---|---|
Gender | Female |
Speciality | Psychologist - Clinical |
Location | 55 Company Street, Christiansted, St. Croix, Virgin Island |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1437385887 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
103TC0700X | Psychologist - Clinical | 04-018-PSY (Virgin Island) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Lucia Rosario Dimeo, PHD Po Box 2520, Kingshill, VI 00851-2520 Ph: () - | Dr Lucia Rosario Dimeo, PHD 55 Company Street, Christiansted, St. Croix, VI 00820 Ph: (340) 713-9029 |
News Archive
A procedure intended to help heal musculoskeletal injuries called platelet-rich plasma therapy, or P.R.P., has created a big buzz in sports medicine and the media in recent years. Tiger Woods reportedly received the procedure for a sore knee and Pittsburgh Steelers' Hines Ward used it for a sprained knee ligament just before playing a key role in the team's 2009 Super Bowl victory.
The latest national survey conducted by the Harvard School of Public Health (HSPH) Project on the Public and Biological Security finds that when faced with a serious outbreak of pandemic flu, a large majority of Americans are willing to make major changes in their lives and cooperate with public health officials' recommendations.
Researchers at Lund University in Sweden believe they have found a method that in the future could help people suffering from epilepsy so severe that all current treatment is ineffective.
XBiotech, a privately held biotechnology company, announced today that the company has been granted Fast Track designation for its anti-cachexia drug Xilonix.
JumpStart Ventures, which invests in and partners with innovative, early-stage companies in Northeast Ohio, announced an investment commitment of $250,000 in drug development company ChanRx. The two-year-old company is developing a pharmaceutical compound to treat atrial fibrillation, a heart condition that affects two million Americans, with 200,000 new cases being diagnosed each year.
› Verified 6 days ago